Senior Project Manager (Early Phase Development)

Position Summary The Senior Project Manager (Sr. PM) is responsible for supporting complex, high-impact asset programs/projects and enterprise projects from initiation through delivery, ensuring alignment with organizational goals and strategic priorities. The Sr. PM will be responsible for co-leading strategic planning and decision-making processes with the DT/ADT/ACT Lead. Reporting to the head of Portfolio and Project Management, this role will ensure that cross-functional teams operate effectively, promote a positive team dynamic, and support the MBX operating model. This role requires strong leadership, exceptional communication skills, and the ability to manage cross-functional teams in a fast-paced environment. Key Responsibilities Build and maintain MBX’s asset and enterprise project plans that include scope, timelines, milestones, deliverables, key Go/No-Go decision points, resources, risks, and budgets. Drive the execution of project plans, manage and update cross-functional timelines, proactively identify potential project risks, and develop mitigation and contingency plans with the team to overcome obstacles and ensure project success. Support and manage cross-functional teams and meetings, which involve scheduling, preparing agendas, taking minutes, and tracking action items. Facilitate decision-making and resolve conflicts efficiently. Recommend and adjust plans as needed to ensure timeline progress and goal achievement. Lead and motivate cross-functional teams to achieve project goals. Review and provide feedback on program-level strategy related documentation such as regulatory meeting packages. Serve as the main point of contact for all project-related communications and reporting, fostering strong relationships with internal teams and external partners. Prepare and present regular status updates to senior leadership. Ensure all project documentation is accurate and up to date. Identify strategic or operational challenges that may affect plan execution while collaborating with the team to recognize risks and formulate mitigation strategies. Work with the Project Management team to develop, refine, and implement project management methodologies, tools, and best practices to enhance overall project effectiveness. Develop and manage in partnership with Finance, the project budget, detailed forecasting and reporting, with a keen focus on cost control and resource optimization, balancing project needs and organizational capacity. Potentially provide leadership, training, mentorship, and coaching to junior PMs. In addition to asset program/project management, Sr. PMs may support enterprise project management, and functional project management if requested. Other responsibilities as assigned. Education & Qualifications Bachelor’s degree in relevant scientific discipline required 6+ years of experience in the pharmaceutical or biotech industry. 6+ years of project management experience managing drug development programs. Requires knowledge and understanding of the drug development process. Project management and analytical skills, including strong organization, prioritization, multi-tasking, and problem-solving skills. Demonstrated ability to deliver results of high quality, on time, and within budget. Strong oral, verbal, and interpersonal communication skills with a bias toward action. Willingness and ability to build and maintain strong, cross-functional relationships within all levels of the department and throughout the organization. Ability to lead and drive results in a cross-functional team environment. Project management professional (PMP) certification preferred. Proficiency in the use of project management tools and techniques (e.g., MS Project, MS Excel, MS PowerPoint, etc.). Travel You will be expected to travel periodically based on the needs of the business to the extent requested by the Company including attendance at Together Weeks, Together Days and functional meetings as requested by the Company. Company Overview MBX Biosciences, Inc. (NASDAQ: MBX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at and follow us on LinkedIn. EEO Statement MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law. #J-18808-Ljbffr MBX Biosciences, Inc.